Amoy Diagnostics
Manufacturing · China · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
39 Dingshan Rd, Xiamen, Anhui, ChinaPhone Number
+86 5926806830Website
www.amoydx.comRevenue
$148.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Amoy Diagnostics
厦门艾德生物医药科技股份有限公司, founded in 2008 by Professor Zheng Limou, focuses on molecular diagnostics in precision oncology. The company specializes in innovative technologies that provide high-quality diagnostic products and services, ensuring patients benefit from precision medicine. Their product offerings include IHC, PCR, NGS, FISH, and nucleic acid extraction products, along with various diagnostic kits. Intended clients include healthcare providers and pharmaceutical companies seeking advanced diagnostic solutions.Explore more
Amoy Diagnostics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Amoy Diagnostics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Amoy Diagnostics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Amoy Diagnostics
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Amoy Diagnostics launches new products
Check out if Amoy Diagnostics is spiking on competitors!
Earning: See what the market has to say on Amoy Diagnostics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Amoy Diagnostics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Amoy Diagnostics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Amoy Diagnostics has new funding data
Recommended Actions
Reach out to Masked Content who joined Amoy Diagnostics as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Amoy Diagnostics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Amoy Diagnostics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Amoy Diagnostics.
Amoy Diagnostics Tech Stack
A closer look at the technologies used by Amoy Diagnostics
Amoy Diagnostics News & Media
AmoyDx Enters into Master Collaboration Agreement with AstraZeneca for Multiple Companion Diagnostics Programs in China, EU and Japan
SHANGHAI, China, April 18, 2022 (GLOBE NEWSWIRE) -- Amoy Diagnostics Co., Ltd (AmoyDx), a China based innovative molecular diagnostics company (SZSE: 300685), today announces that it has entered into a Master Collaboration Agreement (Agreement) with AstraZeneca (LSE/STO/Nasdaq: AZN), a global, science-led biopharmaceutical company. The master collaboration agreement enables the Parties to collaborate in the development and commercialization of AmoyDx assays that may cover any type of indicationNotice Concerning Application for Partial Revision of Manufacturing and Marketing Approval of Companion Diagnostic Reagent for the AmoyDx® Pan Lung Cancer PCR Panel
TOKYO and XIAMEN, China, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that an application for partial revision of manufacturing and marketing approval for AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”), an in vitro diagnostic reagent for multiple antineoplastic agents, was submitted in February 2022 (hereinafter referred to as the "Application for Partial Change").AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for TEPMETKO® (tepotinib)
TOKYO and XIAMEN, China, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) as a companion diagnostic for TEPMETKO® (tepotinib) a Merck KGaA, Darmstadt, Germany product that received approval by the Japanese MHLW in March 2020. TEPMETKO (tepotinib)AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for 9 Targeted Therapies for Use in Patients with Advanced Non-Small Cell Lung Cancer
TOKYO and XIAMEN, China, June 30, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”), an in vitro diagnostic reagent developed as a companion diagnostic for multiple anti-cancer agents, was approved by Ministry of Health, Labour and Welfare (MHLW) for production and marketing in Japan on June 25, 2021. The
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Amoy Diagnostics
Sign Up For FreeTo access detailed company insights
厦门艾德生物医药科技股份有限公司, founded in 2008 by Professor Zheng Limou, focuses on molecular diagnostics in precision oncology. The company specializes in innovative technologies that provide high-quality diagnostic products and services, ensuring patients benefit from precision medicine. Their product offerings include IHC, PCR, NGS, FISH, and nucleic acid ex... Read More
